Accessibility Menu
Achilles Therapeutics Plc logo

Achilles Therapeutics Plc

(NASDAQ) ACHL

This security has been delisted. This page is retained for historical reference.

Achilles Therapeutics Plc last closing stock price
MetricPriceDate
Last closeUSD 1.482025-03-20
Achilles Therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.23%USD 1.422025-03-13
1 month+6.47%USD 1.392025-02-18
3 month+50.85%USD 0.982024-12-20
Year to date+29.82%USD 1.142024-12-31
1 year+14.73%USD 1.292024-03-20
3 year-53.16%USD 3.162022-03-21
Since inception-91.06%USD 16.552021-03-31

ACHL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

ACHL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-41.05%

Return on Capital

-51.20%

Return on Assets

-43.15%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$3.52M

Operating Income

-$72.19M

EBITDA

-$68.42M

Operating Cash Flow

-$30.66M

Capital Expenditure

-$801.63K

Free Cash Flow

-$31.47M

Cash & ST Invst.

$86.05M

Total Debt

$3.62M

Achilles Therapeutics Plc Performance Analysis

Achilles Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
Achilles Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31N/A
Q12024-03-31N/A
Q22024-06-30N/A
Q32024-09-30N/A
Achilles Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -2.13N/A
20222022-12-31USD -1.82-14.8%
20232023-12-31USD -1.75-3.7%
Achilles Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31-11.9%
Q12024-03-3136.2%
Q22024-06-30-36.7%
Q32024-09-30-17.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

204

N/A

Net Income

-$19.60M

-17.5%

EBITDA

-$20.42M

-14.1%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$86.05M

-38.6%

Total Debt

$3.62M

-50.8%

Accounts Receivable

$21.79M

+127.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.62M

-21.6%

Return on Assets

-43.15%

N/A

Return on Invested Capital

-52.09%

N/A

Free Cash Flow

-$17.34K

+3.4%

Operating Cash Flow

-$17.31K

+0.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RPHMReneo Pharmaceuticals, Inc.
$18.20+952.02%
TCRRTCR2 Therapeutics Inc.
$1.48+0.00%
SURFSurface Oncology, Inc.
$1.07-0.93%
KRONKronos Bio, Inc.
$0.88+1.49%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
INTCIntel
$95.04-0.02%
JOBYJoby Aviation
$7.23-0.01%
SPCXSpace Exploration Technologies
$123.99-0.05%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.